Oncogenic mutations in the gene encoding BRAF kinase are driver mutations found in roughly half of human melanoma patients. Remarkably a single lesion, the V600E mutation (BRAF V600E ), is the predominant mutation found in these patients. Oncogenic BRAF V600E constitutively activates MEK-MAPK signaling cascade to promote proliferation and survival as well as protect transformed melanocytes from apoptosis. 1 Selective BRAF V600E inhibitors, vemurafenib and dabrafenib, are effective at halting disease progression or even inducing tumor regression in a high frequency of melanoma patients harboring BRAF V600E mutation. However, melanomas resistant to BRAF V600E inhibitor inevitably arise after a few months of treatment, after which there are no further therapeutic options. The lack of treatment for this aggressive form of melanoma demands a better understanding of tumor progression and regression to prevent resistance and identify novel therapies. 2 The tumor microenvironment consists of tumor cells, stromal cells and a variety of immune cells. Clinically, the increase of tumor-infiltrating T lymphocytes has been shown to correlate with prolonged survival of patients with colon cancer as well as other types of cancers. 3 Increasing the frequency of intratumoral T cells by transferring tumor-specific T cells can also diminish tumor progression in small portion of patients. These findings reveal that immune cells may be able to eliminate tumor cells by recognizing tumor antigens or moieties. However, recent studies have suggested that tumor-infiltrating immune cells may provide both pro-tumorigenic and anti-tumorigenic effects in the tumor microenvironment. The tumor microenvironment is generally immunosuppressive and the accumulation of different immunomodulatory cells, including regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), within the tumor microenvironment can compromise antitumor immunity. 4 Immunotherapies that target checkpoints of immune responses (including PD-1 and CTLA-4 blockade) or the immunomodulatory cells themselves have been shown partially restore antitumor immunity. 5 Host immunity has also been suggested to inhibit melanoma progression in melanoma-bearing mice receiving B-Raf V600E inhibitor treatment, but the underlying immune responses are not well defined. 6 Therefore, understanding how cancer cells promote an immunosuppressive microenvironment in tumors, and, whether the underlying mechanisms can be targeted to activate antitumor responses, are critical, clinically relevant aspects of tumor immunology. The knowledge attained from targeted therapies and chemotherapies may facilitate the development of new treatment regimens that harness the power of the immune system in combating malignant disease.
In our recent study, we first determined the kinetics of both adaptive and innate immune responses during tumor growth using a genetically modified melanoma mouse model (referred as Braf/Pten mice). 7 In this mouse model, melanomas were induced by the oncogenic B-Raf V600E mutation and simultaneous depletion of Pten in melanocytes. 8 Since Braf/Pten mice harbor a common driver mutation and exhibit similar pathophysiological features as those observed in melanoma patients, we took the advantage of this model to examine the immune responses in an immunocompetent setting. We first characterized whether specific immune responses are diminished during tumor progression and, if so, whether these immune responses could be restored after B-Raf V600E inhibitor treatment. We found that Braf/Pten melanomas accumulated multiple immunosuppressive cells during tumor growth, including increased frequencies of intratumoral Tregs, MDSCs, immature tumor-associated macrophages (TAMs), and tumor-infiltrating dendritic cells (TIDCs). Additionally, intratumoral effector CD4 + T cells lost their effector cytokine production and CD40L expression in advanced stage melanomas. Surprisingly, treating tumor-bearing mice with PLX4720, an analog of the B-Raf V600E inhibitor vemurafenib, reduced tumor growth and diminished the frequencies of intratumoral Tregs and MDSCs while increasing the populations of tumorinfiltrating CD4 + and CD8 + T cells. PLX4720 also promoted the maturation of both TAMs and TIDCs. Importantly, more intratumoral CD4 + T cells produced interferon γ (IFNγ) and expressed CD40L in mice receiving B-Raf V600E inhibitor therapy than in mice receiving control treatment. Although the increase in tumor-infiltrating CD8 + T cells has been suggested to impede tumor progression by elimination of cancer cells, the role of intratumoral CD4 + T cells in shaping antitumor immunity has been underappreciated. To our surprise, our results showed that PLX4720 treatment suppresses melanoma growth in a CD4
+ , but not CD8 + , T cell-dependent manner. Our study also revealed that the effector (IFNγ) and helper (CD40L) functions of intratumoral CD4 + T cells might be involved in promoting the maturation of TAMs and TIDCs and preventing the accumulation of MDSCs and Tregs differentially (Fig. 1) . Critically, we demonstrated that treating mice with agonistic anti-CD40 antibody to mimic CD40L could provide significant antitumor effect and promote maturation of TAMs.
Since depletion of CD4 + T cells and inhibition of IFNγ or CD40L significantly blunted PLX4720-mediated antitumor responses, our results suggested that altering the functions of intratumoral CD4 + T cells could be the driving force to restore antitumor immunity in the tumor microenvironment. Of note, blocking IFNγ and CD40L also efficiently inhibited maturation of TAMs and TIDCs in response to PLX4720 therapy. Therefore, it is less likely that the maturation of these intratumoral APCs was induced by elevation of damage-associated molecular patterns (DAMPs) subsequent to B-Raf V600E inhibitor therapy. 9 Given that B-Raf V600E inhibitors targets mutant B-Raf kinase and affect melanoma cells' proliferation and metabolism, we hypothesize that B-Raf V600E inhibitors may alter certain activities of melanoma cells that normally allow them to suppress T helper cell type 1 (T H 1) effector and helper functions.
In summary, these findings inspire conceptual advances on the roles of immune signaling in BRAF V600E inhibitor-mediated antitumor responses. Most importantly, treating Braf/Pten mice with agonistic anti-CD40 mAb is a proof-of-concept that re-introduction of CD40L:CD40 signal could impede tumor growth, suggesting that diminished CD40L expression on intratumoral CD4 + T cells may be involved in immune escape. Of note, we showed that the therapeutic benefit of agonistic anti-CD40 mAb is T cell-independent. Therefore, an important future direction would be exploring whether combining agonistic anti-CD40 mAb with immunotherapies targeting inhibitory checkpoints can elicit stronger antitumor response in both BRAF V600E inhibitor-sensitive and -resistant melanomas. Additionally, determining whether the CD40L expression level after BRAF V600E inhibitor therapy correlates with the antitumor responses and the emergence of resistant melanomas will be of great interest for clinical applications.
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